Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations
BACKGROUND: Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from tw...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2025-04-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000004/art00004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850212362110369792 |
|---|---|
| author | G. Hoddinott H.R. Draper N. Vanqa S. Myeni S. Staples T. Sachs M. Raffique N. Tshethu M. Palmer L. Viljoen K. Inabathina R. Taneja A.C. Hesseling A.J. Garcia-Prats |
| author_facet | G. Hoddinott H.R. Draper N. Vanqa S. Myeni S. Staples T. Sachs M. Raffique N. Tshethu M. Palmer L. Viljoen K. Inabathina R. Taneja A.C. Hesseling A.J. Garcia-Prats |
| author_sort | G. Hoddinott |
| collection | DOAJ |
| description | BACKGROUND: Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from two generic manufacturers. METHODS: This was a randomised, cross-sectional ‘swish-and-spit’ taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5–17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends’ acceptability using summary, comparative, and ranking statistics. RESULTS: Ninety-seven and 96 children contributed data for the MFX and LZD drug blends, respectively. For both manufacturers’ MFX blends, the Friedman test showed children had a statistically significant preference for novel options over the Existing blend (Q(2) = 24,937; P < 0.001, and Q(2) = 21.213; P < 0.001, respectively). Even the most preferred MFX blend had sub-optimal acceptability, especially for one manufacturer. Children did not have a clear preference for both manufacturers’ LZD blends. These findings were not influenced by age, sex, or ethnic group. CONCLUSION: Children across a broad age spectrum can provide meaningful input on the palatability preferences of TB drug formulations. Novel MFX formulation blends were recommended for development, but acceptability remains suboptimal. |
| format | Article |
| id | doaj-art-861ef8dbd37140caa3fb1cb2ad22ace1 |
| institution | OA Journals |
| issn | 3005-7590 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-861ef8dbd37140caa3fb1cb2ad22ace12025-08-20T02:09:21ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902025-04-012420821610.5588/ijtldopen.24.05464Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulationsG. Hoddinott0H.R. Draper1N. Vanqa2S. Myeni3S. Staples4T. Sachs5M. Raffique6N. Tshethu7M. Palmer8L. Viljoen9K. Inabathina10R. Taneja11A.C. Hesseling12A.J. Garcia-Prats13Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;THINK Tuberculosis and HIV Investigative Network (RF) NPC, Durban, South Africa;THINK Tuberculosis and HIV Investigative Network (RF) NPC, Durban, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Global Alliance for TB Drug Development (TB Alliance), New York, NY, USA;Global Alliance for TB Drug Development (TB Alliance), New York, NY, USA;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;BACKGROUND: Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from two generic manufacturers. METHODS: This was a randomised, cross-sectional ‘swish-and-spit’ taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5–17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends’ acceptability using summary, comparative, and ranking statistics. RESULTS: Ninety-seven and 96 children contributed data for the MFX and LZD drug blends, respectively. For both manufacturers’ MFX blends, the Friedman test showed children had a statistically significant preference for novel options over the Existing blend (Q(2) = 24,937; P < 0.001, and Q(2) = 21.213; P < 0.001, respectively). Even the most preferred MFX blend had sub-optimal acceptability, especially for one manufacturer. Children did not have a clear preference for both manufacturers’ LZD blends. These findings were not influenced by age, sex, or ethnic group. CONCLUSION: Children across a broad age spectrum can provide meaningful input on the palatability preferences of TB drug formulations. Novel MFX formulation blends were recommended for development, but acceptability remains suboptimal.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000004/art00004rifampicin-resistantmoxifloxacinlinezolidacceptabilitypalatabilitychildren |
| spellingShingle | G. Hoddinott H.R. Draper N. Vanqa S. Myeni S. Staples T. Sachs M. Raffique N. Tshethu M. Palmer L. Viljoen K. Inabathina R. Taneja A.C. Hesseling A.J. Garcia-Prats Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations IJTLD Open rifampicin-resistant moxifloxacin linezolid acceptability palatability children |
| title | Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations |
| title_full | Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations |
| title_fullStr | Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations |
| title_full_unstemmed | Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations |
| title_short | Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations |
| title_sort | children s preferences among six novel moxifloxacin and linezolid dispersible tablet formulations |
| topic | rifampicin-resistant moxifloxacin linezolid acceptability palatability children |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000004/art00004 |
| work_keys_str_mv | AT ghoddinott childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT hrdraper childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT nvanqa childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT smyeni childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT sstaples childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT tsachs childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT mraffique childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT ntshethu childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT mpalmer childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT lviljoen childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT kinabathina childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT rtaneja childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT achesseling childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations AT ajgarciaprats childrenspreferencesamongsixnovelmoxifloxacinandlinezoliddispersibletabletformulations |